BioNotebook: Biotech opportunities in EY report; Loxo raises $24m; Akorn buying VersaPharm; Alder, Radius, Agile IPO news

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Ernst & Young's recent report Progressions: Navigating the payer landscape noted the lack of trust that health care payers have for pharmaceutical companies, but if you look closely EY's survey of payers and industry revealed opportunities for biotechnology firms to help big pharma engage with private insurers and government agencies that cover drug costs (scripintelligence.com, 7 May 2014).

Ernst & Young's recent report Progressions: Navigating the payer landscape noted the lack of trust that health care payers have for pharmaceutical companies, but if you look closely EY's survey of payers and industry revealed opportunities for biotechnology firms to help big pharma engage with private insurers and government agencies that cover drug costs (scripintelligence.com, 7 May 2014).

EY lead analyst Gautam Jaggi, who served as managing editor for the Progressions report, told Scrip that drug makers still...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anti-infective

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand

 
• By Andrew McConaghie

The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.  

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.